Results: 1-14 |
Results: 14

Authors: Rudin, CM Holmlund, J Fleming, GF Mani, S Stadler, WM Schumm, P Monia, BP Johnston, JF Geary, R Yu, RZ Kwoh, TJ Dorr, FA Ratain, MJ
Citation: Cm. Rudin et al., Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer, CLIN CANC R, 7(5), 2001, pp. 1214-1220

Authors: Fleming, GF McElnay, JC Hughes, CM Sheridan, J Strang, J
Citation: Gf. Fleming et al., The role of the community pharmacist in drug abuse: a comparison of service provision between Northern Ireland and England/Wales, PHARM WORLD, 23(1), 2001, pp. 13-16

Authors: Recht, A Edge, SB Solin, LJ Robinson, DS Estabrook, A Fine, RE Fleming, GF Formenti, S Hudis, C Kirshner, JJ Krause, DA Kuske, RR Langer, AS Sledge, GW Whelan, TJ Pfister, DG
Citation: A. Recht et al., Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology, J CL ONCOL, 19(5), 2001, pp. 1539-1569

Authors: Fleming, GF Fowler, JM Waggoner, SE Copeland, LJ Greer, BE Horowitz, I Sutton, G Schilder, RJ Fracasso, PM Ball, HG McGuire, WP
Citation: Gf. Fleming et al., Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: A Gynecologic Oncology Group Study, J CL ONCOL, 19(4), 2001, pp. 1021-1029

Authors: Fleming, GF Waggoner, SE Rotmensch, J Langhauser, C
Citation: Gf. Fleming et al., Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel, AM J CL ONC, 24(1), 2001, pp. 52-57

Authors: Laport, GG Fleming, GF Waggoner, S Zimmerman, TM Grinblatt, DL Williams, SF
Citation: Gg. Laport et al., A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer, BONE MAR TR, 27(7), 2001, pp. 677-681

Authors: Benz, CC Hilakivi-Clarke, L Conzen, S Dorn, RV Fleming, GF Grant, K Greene, G Hellman, S Henderson, C Hoover, R Hryniuk, W Jeffrey, S Lippman, M Lung, J Mitchell, M Pike, M
Citation: Cc. Benz et al., Expedition inspiration consensus 2001, BREAST CANC, 70(3), 2001, pp. 213-219

Authors: Mundt, AJ Rotmensch, J Waggoner, SE Yamada, D Langhauser, C Fleming, GF
Citation: Aj. Mundt et al., Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies, GYNECOL ONC, 82(2), 2001, pp. 333-337

Authors: Poelman, SM Adeyanju, MO Robertson, MA Recant, WM Karrison, T Fleming, GF Olopade, OI Conzen, SD
Citation: Sm. Poelman et al., Human breast cancer susceptibility to paclitaxel therapy is independent ofBcl-2 expression, CLIN CANC R, 6(10), 2000, pp. 4043-4048

Authors: Baidas, SM Winer, EP Fleming, GF Harris, L Pluda, JM Crawford, JG Yamauchi, H Isaacs, C Hanfelt, J Tefft, M Flockhart, D Johnson, MD Hawkins, MJ Lippman, ME Hayes, DF
Citation: Sm. Baidas et al., Phase II evaluation of thalidomide in patients with metastatic breast cancer, J CL ONCOL, 18(14), 2000, pp. 2710-2717

Authors: Goh, BC Fleming, GF Janisch, L Vogelzang, NJ Stadler, WM Ratain, MJ
Citation: Bc. Goh et al., Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations, CANC CHEMOT, 45(6), 2000, pp. 489-494

Authors: Fleming, GF Roth, BJ Baker, SD Sutton, GP Look, KY Muggia, FM Fracasso, PM McGuire, WP
Citation: Gf. Fleming et al., Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma - A gynecologic oncology group study, AM J CL ONC, 23(6), 2000, pp. 609-613

Authors: Ryan, CW Fleming, GF Janisch, L Ratain, MJ
Citation: Cw. Ryan et al., A phase I study of liposomal doxorubicin (Doxil) with topotecan, AM J CL ONC, 23(3), 2000, pp. 297-300

Authors: DeMario, MD Ratain, MJ Vogelzang, NJ Mani, S Vokes, EE Fleming, GF Melton, K Johnson, S Benner, S Lebwohl, D
Citation: Md. Demario et al., A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14days every 28 days, CANC CHEMOT, 43(5), 1999, pp. 385-388
Risultati: 1-14 |